ALKS
Alkermes plc.
+0.54 (+1.17%)46.61USD449K成交股數7.8B市值122.7本益比(近四季)4.7股價營收比+27.0%營收年增(近四季)2026-10-28下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 10 · 4.2M · 4 |
| 其中 10b5-1 計畫賣出 | 9 筆 |
| 近 180 天 買進 · 賣出金額 | 0.00 · 6.2M |
| 近 180 天 淨額 | −6.2M |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-03 | 09-03 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S 公開市場賣出(10b5-1) | 2.0K | 48.01 | 98K | 223K | SEC |
| 2026-09-01 | 09-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M 選擇權執行 | 5.0K | 24.59 | 123K | 74.4K | SEC |
| 2026-09-01 | 09-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S 公開市場賣出(10b5-1) | 9.0K | 46.99 | 423K | 65.4K | SEC |
| 2026-08-17 | 08-17 | Nichols Christian Todd | SVP, Chief Commercial Officer | S 公開市場賣出(10b5-1) | 6.9K | 49.19 | 340K | 103K | SEC |
| 2026-08-17 | 08-17 | Nichols Christian Todd | SVP, Chief Commercial Officer | S 公開市場賣出(10b5-1) | 664 | 49.65 | 33K | 102K | SEC |
| 2026-08-03 | 08-03 | snyderman nancy lynn MD | Director | S 公開市場賣出 | 44.5K | 50.35 | 2.2M | 15.4K | SEC |
| 2026-08-03 | 08-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M 選擇權執行 | 104 | 19.34 | 2K | 73.5K | SEC |
| 2026-08-03 | 08-03 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S 公開市場賣出(10b5-1) | 2.0K | 48.58 | 99K | 225K | SEC |
| 2026-08-03 | 08-03 | snyderman nancy lynn MD | Director | M 選擇權執行 | 16.5K | 46.72 | 772K | 59.9K | SEC |
| 2026-08-03 | 08-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M 選擇權執行 | 4.9K | 24.59 | 120K | 78.4K | SEC |
| 2026-08-03 | 08-03 | snyderman nancy lynn MD | Director | M 選擇權執行 | 27.9K | 46.72 | 1.3M | 43.3K | SEC |
| 2026-08-03 | 08-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S 公開市場賣出(10b5-1) | 9.0K | 48.58 | 437K | 69.4K | SEC |
| 2026-07-06 | 07-06 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S 公開市場賣出(10b5-1) | 2.0K | 54.03 | 110K | 227K | SEC |
| 2026-07-01 | 07-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S 公開市場賣出(10b5-1) | 8.3K | 51.46 | 427K | 74.1K | SEC |
| 2026-07-01 | 07-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M 選擇權執行 | 5.0K | 19.34 | 97K | 82.4K | SEC |
| 2026-07-01 | 07-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S 公開市場賣出(10b5-1) | 700 | 52.13 | 36K | 73.4K | SEC |
| 2026-06-12 | 06-12 | Wright Christopher I | Director | S 公開市場賣出(10b5-1) | 2.0K | 45.10 | 90K | 25.7K | SEC |
| 2026-06-04 | 06-04 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S 公開市場賣出(10b5-1) | 2.0K | 43.05 | 88K | 230K | SEC |
| 2026-06-01 | 06-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M 選擇權執行 | 5.0K | 19.34 | 97K | 86.4K | SEC |
| 2026-06-01 | 06-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S 公開市場賣出(10b5-1) | 9.0K | 41.67 | 375K | 77.4K | SEC |
| 2026-05-29 | 05-29 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M 選擇權執行 | 3.4K | 20.03 | 68K | 11.1K | SEC |
| 2026-05-29 | 05-29 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | S 公開市場賣出 | 16.2K | 42.36 | 687K | 7.7K | SEC |
| 2026-05-29 | 05-29 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M 選擇權執行 | 12.8K | 19.34 | 248K | 23.9K | SEC |
| 2026-05-21 | 05-22 | Lurker Nancy | Director | F 繳稅扣股 | 1.5K | 36.95 | 55K | 18.2K | SEC |
| 2026-05-21 | 05-22 | LAURENCIN CATO T | Director | F 繳稅扣股 | 1.5K | 36.95 | 55K | 33.8K | SEC |
| 2026-05-21 | 05-22 | LAURENCIN CATO T | Director | M 選擇權執行 | 6.1K | – | – | 35.2K | SEC |
| 2026-05-21 | 05-22 | GAYNOR RICHARD | Director | F 繳稅扣股 | 1.5K | 36.95 | 55K | 35.8K | SEC |
| 2026-05-21 | 05-22 | Lurker Nancy | Director | M 選擇權執行 | 6.1K | – | – | 19.7K | SEC |
| 2026-05-21 | 05-22 | Cooke Shane | Director | F 繳稅扣股 | 3.2K | 36.95 | 118K | 107K | SEC |
| 2026-05-21 | 05-22 | GAYNOR RICHARD | Director | M 選擇權執行 | 6.1K | – | – | 37.2K | SEC |
| 2026-05-21 | 05-22 | Cooke Shane | Director | M 選擇權執行 | 6.1K | – | – | 110K | SEC |
| 2026-05-21 | 05-22 | MCKEON BRIAN P | Director | M 選擇權執行 | 6.1K | – | – | 40.0K | SEC |
| 2026-05-21 | 05-22 | Wright Christopher I | Director | M 選擇權執行 | 6.1K | – | – | 29.2K | SEC |
| 2026-05-21 | 05-22 | Wilson Frank Anders | Director | M 選擇權執行 | 6.1K | – | – | 37.2K | SEC |
| 2026-05-21 | 05-22 | Wright Christopher I | Director | F 繳稅扣股 | 1.5K | 36.95 | 55K | 27.7K | SEC |
| 2026-05-21 | 05-22 | snyderman nancy lynn MD | Director | F 繳稅扣股 | 1.5K | 36.95 | 55K | 15.4K | SEC |
| 2026-05-21 | 05-22 | Wilson Frank Anders | Director | F 繳稅扣股 | 1.5K | 36.95 | 55K | 35.8K | SEC |
| 2026-05-21 | 05-22 | MCKEON BRIAN P | Director | F 繳稅扣股 | 1.5K | 36.95 | 55K | 38.5K | SEC |
| 2026-05-21 | 05-22 | snyderman nancy lynn MD | Director | M 選擇權執行 | 6.1K | – | – | 16.9K | SEC |
| 2026-05-04 | 05-04 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S 公開市場賣出(10b5-1) | 2.0K | 33.20 | 68K | 232K | SEC |
| 2026-05-01 | 05-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M 選擇權執行 | 5.0K | 19.34 | 97K | 90.4K | SEC |
| 2026-05-01 | 05-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S 公開市場賣出(10b5-1) | 9.0K | 33.40 | 301K | 81.4K | SEC |
| 2026-04-11 | 04-13 | Lurker Nancy | Director | F 繳稅扣股 | 901 | 33.36 | 30K | 13.6K | SEC |
| 2026-04-11 | 04-13 | Lurker Nancy | Director | M 選擇權執行 | 3.8K | – | – | 14.5K | SEC |
| 2026-04-06 | 04-06 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S 公開市場賣出(10b5-1) | 2.0K | 34.57 | 70K | 234K | SEC |
| 2026-04-01 | 04-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M 選擇權執行 | 5.0K | 19.34 | 97K | 94.4K | SEC |
| 2026-04-01 | 04-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S 公開市場賣出(10b5-1) | 9.0K | 35.51 | 320K | 85.4K | SEC |
| 2026-03-03 | 03-04 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S 公開市場賣出(10b5-1) | 2.0K | 29.76 | 61K | 236K | SEC |
| 2026-03-02 | 03-04 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S 公開市場賣出(10b5-1) | 9.0K | 29.72 | 267K | 89.4K | SEC |
| 2026-03-02 | 03-04 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | S 公開市場賣出(10b5-1) | 6.9K | 29.29 | 202K | 7.7K | SEC |
| 2026-03-02 | 03-04 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M 選擇權執行 | 5.0K | 19.34 | 97K | 98.4K | SEC |
| 2026-03-02 | 03-04 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | S 公開市場賣出(10b5-1) | 2.0K | 29.29 | 60K | 238K | SEC |
| 2026-03-02 | 03-04 | Nichols Christian Todd | SVP, Chief Commercial Officer | S 公開市場賣出(10b5-1) | 6.0K | 30.00 | 180K | 110K | SEC |
| 2026-02-26 | 02-27 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M 選擇權執行 | 2.7K | – | – | 15.4K | SEC |
| 2026-02-26 | 02-27 | Nichols Christian Todd | SVP, Chief Commercial Officer | F 繳稅扣股 | 2.4K | 30.73 | 74K | 116K | SEC |
| 2026-02-26 | 02-27 | Nichols Christian Todd | SVP, Chief Commercial Officer | M 選擇權執行 | 5.4K | – | – | 118K | SEC |
| 2026-02-26 | 02-27 | Jackson Blair Curtis | EVP, Chief Operating Officer | F 繳稅扣股 | 3.7K | 30.73 | 114K | 241K | SEC |
| 2026-02-26 | 02-27 | Jackson Blair Curtis | EVP, Chief Operating Officer | M 選擇權執行 | 8.3K | – | – | 245K | SEC |
| 2026-02-26 | 02-27 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F 繳稅扣股 | 3.0K | 30.73 | 94K | 93.4K | SEC |
| 2026-02-26 | 02-27 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M 選擇權執行 | 6.9K | – | – | 96.4K | SEC |
| 2026-02-26 | 02-27 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F 繳稅扣股 | 3.0K | 30.73 | 94K | 240K | SEC |
| 2026-02-26 | 02-27 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | F 繳稅扣股 | 808 | 30.73 | 25K | 14.6K | SEC |
| 2026-02-26 | 02-27 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M 選擇權執行 | 6.9K | – | – | 243K | SEC |
| 2026-02-23 | 02-25 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M 選擇權執行 | 7.7K | – | – | 239K | SEC |
| 2026-02-23 | 02-25 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F 繳稅扣股 | 3.4K | 32.19 | 110K | 236K | SEC |
| 2026-02-23 | 02-25 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | F 繳稅扣股 | 672 | 32.19 | 22K | 12.7K | SEC |
| 2026-02-23 | 02-25 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | M 選擇權執行 | 2.3K | – | – | 13.3K | SEC |
| 2026-02-23 | 02-25 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M 選擇權執行 | 7.7K | – | – | 93.0K | SEC |
| 2026-02-23 | 02-25 | Nichols Christian Todd | SVP, Chief Commercial Officer | F 繳稅扣股 | 2.8K | 32.19 | 92K | 113K | SEC |
| 2026-02-23 | 02-25 | Nichols Christian Todd | SVP, Chief Commercial Officer | M 選擇權執行 | 6.4K | – | – | 116K | SEC |
| 2026-02-23 | 02-25 | Jackson Blair Curtis | EVP, Chief Operating Officer | F 繳稅扣股 | 3.9K | 32.19 | 125K | 237K | SEC |
| 2026-02-23 | 02-25 | Jackson Blair Curtis | EVP, Chief Operating Officer | M 選擇權執行 | 8.7K | – | – | 241K | SEC |
| 2026-02-23 | 02-25 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F 繳稅扣股 | 3.4K | 32.19 | 110K | 89.6K | SEC |
| 2026-02-19 | 02-20 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M 選擇權執行 | 7.7K | – | – | 88.7K | SEC |
| 2026-02-19 | 02-20 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | F 繳稅扣股 | 3.4K | 32.00 | 109K | 232K | SEC |
| 2026-02-19 | 02-20 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | M 選擇權執行 | 7.7K | – | – | 235K | SEC |
| 2026-02-19 | 02-20 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F 繳稅扣股 | 3.4K | 32.00 | 109K | 85.3K | SEC |
| 2026-02-19 | 02-20 | Jackson Blair Curtis | EVP, Chief Operating Officer | M 選擇權執行 | 9.3K | – | – | 236K | SEC |
| 2026-02-19 | 02-20 | Jackson Blair Curtis | EVP, Chief Operating Officer | F 繳稅扣股 | 4.1K | 32.00 | 132K | 232K | SEC |
| 2026-02-19 | 02-20 | Nichols Christian Todd | SVP, Chief Commercial Officer | M 選擇權執行 | 6.0K | – | – | 111K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| BlackRock, Inc. | 29.2M | 1.5B | 新進 | 新進 |
| BAKER BROS. ADVISORS LP | 10.0M | 525M | 新進 | 新進 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 9.5M | 497M | 新進 | 新進 |
| STATE STREET CORP | 9.2M | 480M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.5M | 394M | 新進 | 新進 |
| 文藝復興 RENAISSANCE TECHNOLOGIES LLC | 6.5M | 339M | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 4.5M | 235M | 新進 | 新進 |
| DIMENSIONAL FUND ADVISORS LP | 4.2M | 220M | 新進 | 新進 |
| Deep Track Capital, LP | 4.0M | 210M | 新進 | 新進 |
| AMERICAN CENTURY COMPANIES INC | 4.0M | 207M | 新進 | 新進 |
| Holocene Advisors, LP | 3.6M | 189M | 新進 | 新進 |
| Commodore Capital LP | 3.0M | 157M | 新進 | 新進 |
| WELLINGTON MANAGEMENT GROUP LLP | 2.8M | 147M | 新進 | 新進 |
| PRIMECAP MANAGEMENT CO/CA/ | 2.5M | 132M | 新進 | 新進 |
| FIRST TRUST ADVISORS LP | 2.4M | 127M | 新進 | 新進 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.3M | 122M | 新進 | 新進 |
| Nuveen, LLC | 2.3M | 122M | 新進 | 新進 |
| 挪威主權基金 NORGES BANK | 2.2M | 113M | 新進 | 新進 |
| BVF INC/IL | 2.2M | 113M | 新進 | 新進 |
| GOLDMAN SACHS GROUP INC | 2.0M | 106M | 新進 | 新進 |
| Bain Capital Life Sciences Investors, LLC | 1.9M | 102M | 新進 | 新進 |
| NORTHERN TRUST CORP | 1.8M | 96.0M | 新進 | 新進 |
| MORGAN STANLEY | 1.8M | 91.8M | 新進 | 新進 |
| RTW INVESTMENTS, LP | 1.7M | 87.6M | 新進 | 新進 |
| 城堡 CITADEL ADVISORS LLC | 1.6M | 86.2M | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 425 +35 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 425 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 178M · 100.0% |
| 合計季末市值 | 8.8B |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 14.7M |
|---|---|
| 與上期比 | -0.3% |
| 佔流通股數 | 8.77% |
| 日均成交量 | 1.2M |
| 回補天數 | 11.8 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 14.7M | -0.3% | 8.77% | 1.2M | 11.8 |
| 2026-08-14 | 14.8M | +2.5% | 8.80% | 1.4M | 10.2 |
| 2026-07-31 | 14.4M | -4.1% | 8.59% | 1.9M | 7.7 |
| 2026-07-15 | 15.0M | -14.0% | 8.95% | 1.6M | 9.1 |
| 2026-06-30 | 17.5M | -2.8% | 10.41% | 3.6M | 4.8 |
| 2026-06-15 | 18.0M | +3.5% | 10.71% | 1.9M | 9.5 |
| 2026-05-29 | 17.4M | -5.0% | 10.35% | 2.1M | 8.5 |
| 2026-05-15 | 18.3M | -7.5% | 10.89% | 2.4M | 7.6 |
| 2026-04-30 | 19.8M | +0.4% | 11.78% | 1.6M | 12.6 |
| 2026-04-15 | 19.7M | +3.5% | 11.73% | 2.4M | 8.2 |
| 2026-03-31 | 19.0M | -7.7% | 11.33% | 3.2M | 5.9 |
| 2026-03-13 | 20.6M | +13.2% | 12.28% | 2.2M | 9.4 |
| 2026-02-27 | 18.2M | +2.1% | 10.85% | 2.0M | 9.2 |
| 2026-02-13 | 17.8M | -6.2% | 10.62% | 1.5M | 11.7 |
| 2026-01-30 | 19.0M | -12.3% | 11.32% | 2.4M | 7.8 |
| 2026-01-15 | 21.7M | -0.8% | 12.91% | 2.1M | 10.5 |
| 2025-12-31 | 21.8M | +9.0% | 13.02% | 1.5M | 14.4 |
| 2025-12-15 | 20.0M | +6.4% | 11.94% | 1.7M | 11.6 |
| 2025-11-28 | 18.8M | +8.9% | 11.22% | 2.1M | 9.0 |
| 2025-11-14 | 17.3M | +8.8% | 10.31% | 3.6M | 4.8 |
| 2025-10-31 | 15.9M | +10.4% | 9.48% | 2.7M | 5.9 |
| 2025-10-15 | 14.4M | -5.3% | 8.58% | 1.7M | 8.4 |
| 2025-09-30 | 15.2M | +1.1% | 9.07% | 2.0M | 7.5 |
| 2025-09-15 | 15.1M | +13.2% | 8.98% | 2.7M | 5.7 |
| 2025-08-29 | 13.3M | -3.6% | 7.93% | 1.3M | 10.1 |
| 2025-08-15 | 13.8M | -0.0% | 8.23% | 1.3M | 10.7 |